Dillon & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.52M | Sell |
7,024
-47
| -0.7% | -$10.4K | 0.21% | 46 |
|
|
2025
Q4 | $1.61M | Hold |
7,071
| – | – | 0.21% | 45 |
|
|
2025
Q3 | $1.64M | Buy |
7,071
+30
| +0.4% | +$6.11K | 0.21% | 46 |
|
|
2025
Q2 | $1.31M | Buy |
7,041
+227
| +3% | +$42.2K | 0.18% | 49 |
|
|
2025
Q1 | $1.43M | Sell |
6,814
-130
| -2% | -$25.3K | 0.21% | 50 |
|
|
2024
Q4 | $1.24M | Buy |
6,944
+30
| +0.4% | +$5.52K | 0.17% | 53 |
|
|
2024
Q3 | $1.36M | Buy |
6,914
+52
| +0.8% | +$9.71K | 0.19% | 51 |
|
|
2024
Q2 | $1.18M | Hold |
6,862
| – | – | 0.17% | 55 |
|
|
2024
Q1 | $1.25M | Buy |
6,862
+201
| +3% | +$34.6K | 0.2% | 52 |
|
|
2023
Q4 | $1.03M | Hold |
6,661
| – | – | 0.19% | 53 |
|
|
2023
Q3 | $992K | Buy |
6,661
+219
| +3% | +$32.1K | 0.19% | 52 |
|
|
2023
Q2 | $870K | Sell |
6,442
-361
| -5% | -$52.9K | 0.16% | 55 |
|
|
2023
Q1 | $1.08M | Sell |
6,803
-1,916
| -22% | -$293K | 0.21% | 53 |
|
|
2022
Q4 | $1.41M | Sell |
8,719
-1,105
| -11% | -$169K | 0.31% | 51 |
|
|
2022
Q3 | $1.32M | Sell |
9,824
-200
| -2% | -$28.7K | 0.31% | 49 |
|
|
2022
Q2 | $1.53M | Sell |
10,024
-100
| -1% | -$15.3K | 0.35% | 46 |
|
|
2022
Q1 | $1.64M | Sell |
10,124
-2,492
| -20% | -$362K | 0.31% | 43 |
|
|
2021
Q4 | $1.7M | Sell |
12,616
-173
| -1% | -$20.4K | 0.3% | 45 |
|
|
2021
Q3 | $1.38M | Buy |
12,789
+4
| +0% | +$457 | 0.26% | 44 |
|
|
2021
Q2 | $1.45M | Sell |
12,785
-100
| -0.8% | -$11.3K | 0.28% | 43 |
|
|
2021
Q1 | $1.39M | Sell |
12,885
-3,273
| -20% | -$350K | 0.3% | 44 |
|
|
2020
Q4 | $1.73M | Hold |
16,158
| – | – | 0.38% | 40 |
|
|
2020
Q3 | $1.42M | Buy |
16,158
+102
| +0.6% | +$9.6K | 0.34% | 41 |
|
|
2020
Q2 | $1.57M | Sell |
16,056
-75
| -0.5% | -$6.6K | 0.43% | 39 |
|
|
2020
Q1 | $1.23M | Sell |
16,131
-3,535
| -18% | -$301K | 0.41% | 40 |
|
|
2019
Q4 | $1.75M | Sell |
19,666
-675
| -3% | -$56K | 0.49% | 39 |
|
|
2019
Q3 | $1.55M | Sell |
20,341
-2,275
| -10% | -$156K | 0.47% | 39 |
|
|
2019
Q2 | $1.65M | Sell |
22,616
-26,930
| -54% | -$2.12M | 0.51% | 38 |
|
|
2019
Q1 | $4.01M | Sell |
49,546
-59,786
| -55% | -$4.89M | 1.3% | 30 |
|
|
2018
Q4 | $10.1M | Sell |
109,332
-2,551
| -2% | -$224K | 3.83% | 7 |
|
|
2018
Q3 | $10.6M | Sell |
111,883
-2,600
| -2% | -$247K | 3.52% | 7 |
|
|
2018
Q2 | $10.6M | Sell |
114,483
-3,377
| -3% | -$330K | 3.93% | 7 |
|
|
2018
Q1 | $11.2M | Sell |
117,860
-3,256
| -3% | -$358K | 4.33% | 5 |
|
|
2017
Q4 | $11.7M | Sell |
121,116
-873
| -0.7% | -$82.3K | 4.43% | 5 |
|
|
2017
Q3 | $10.9M | Sell |
121,989
-1,103
| -0.9% | -$84K | 4.28% | 5 |
|
|
2017
Q2 | $8.99M | Sell |
123,092
-993
| -0.8% | -$66.8K | 3.7% | 8 |
|
|
2017
Q1 | $8.07M | Sell |
124,085
-1,566
| -1% | -$98.5K | 3.43% | 9 |
|
|
2016
Q4 | $7.92M | Sell |
125,651
-404
| -0.3% | -$24.7K | 3.6% | 8 |
|
|
2016
Q3 | $7.94M | Sell |
126,055
-2,379
| -2% | -$154K | 3.66% | 8 |
|
|
2016
Q2 | $7.96M | Sell |
128,434
-452
| -0.4% | -$27.5K | 3.66% | 8 |
|
|
2016
Q1 | $7.35M | Buy |
128,886
+1,528
| +1% | +$85.2K | 3.41% | 9 |
|
|
2015
Q4 | $7.51M | Buy |
127,358
+3,306
| +3% | +$190K | 3.63% | 10 |
|
|
2015
Q3 | $6.7M | Buy |
124,052
+3,300
| +3% | +$215K | 3.35% | 11 |
|
|
2015
Q2 | $8.09M | Buy |
120,752
+859
| +0.7% | +$56.1K | 3.94% | 5 |
|
|
2015
Q1 | $7.07M | Buy |
119,893
+267
| +0.2% | +$16.1K | 3.4% | 11 |
|
|
2014
Q4 | $7.78M | Buy |
119,626
+1,627
| +1% | +$103K | 3.78% | 8 |
|
|
2014
Q3 | $6.84M | Buy |
117,999
+190
| +0.2% | +$10.5K | 3.49% | 10 |
|
|
2014
Q2 | $6.6M | Sell |
117,809
-1,685
| -1% | -$88.4K | 3.38% | 10 |
|
|
2014
Q1 | $6.09M | Sell |
119,494
-511
| -0.4% | -$25.8K | 3.26% | 11 |
|
|
2013
Q4 | $6.36M | Sell |
120,005
-4,410
| -4% | -$217K | 3.43% | 10 |
|
|
2013
Q3 | $6.22M | Sell |
124,415
-8,084
| -6% | -$358K | 3.48% | 10 |
|
|
2013
Q2 | $5.43M | Buy |
+132,499
| New | +$5.79M | 3.48% | 10 |
|
Other funds holding ABBV
VCM
VPM
Dillon & Associates's ABBV Position: Q1 2026 in Review
Dillon & Associates reduced its AbbVie (ABBV) stake by 0.66% in Q1 2026, selling an estimated $10.4K and leaving 7,024 shares worth $1.52M. The position accounts for 0.21% of the portfolio, ranked #46.
Dillon & Associates first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.7M in Q4 2017. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Dillon & Associates held 7,024 shares of AbbVie worth $1.52M as of Q1 2026.
- Dillon & Associates sold 47 AbbVie shares in Q1 2026, an estimated $10.4K.
- AbbVie made up 0.21% of Dillon & Associates's portfolio in Q1 2026, its #46 holding.
- Dillon & Associates first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Dillon & Associates's AbbVie position peaked at $11.7M in Q4 2017.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.